Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared

Biotech SG&A Spending: A Decade of Strategic Shifts

__timestampAmicus Therapeutics, Inc.Intra-Cellular Therapies, Inc.
Wednesday, January 1, 20142071700010337679
Thursday, January 1, 20154726900018187286
Friday, January 1, 20167115100024758063
Sunday, January 1, 20178867100023666957
Monday, January 1, 201812720000030099855
Tuesday, January 1, 201916986100064947625
Wednesday, January 1, 2020156407000186363444
Friday, January 1, 2021192710000272611040
Saturday, January 1, 2022213041000358782000
Sunday, January 1, 2023275270000409864000
Loading chart...

Infusing magic into the data realm

SG&A Spending Patterns: A Tale of Two Biotechs

In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting SG&A spending patterns. From 2014 to 2023, Amicus Therapeutics increased its SG&A expenses by over 1,200%, peaking in 2023. Meanwhile, Intra-Cellular Therapies saw a staggering rise of nearly 3,900% in the same period, reflecting its aggressive market expansion strategy. Notably, in 2020, Intra-Cellular Therapies surpassed Amicus in SG&A spending, marking a pivotal shift in their financial strategies. These trends highlight the dynamic nature of the biotech industry, where companies must balance innovation with operational efficiency to thrive. As these two companies continue to evolve, their SG&A strategies will likely play a crucial role in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025